A new report from the Alliance of Regenerative Medicine shows what a record year the sector had in 2017 with a 78.5 percent year-over-year funding increase to more than $7.5 billion.
Gilead has been looking for ways to add to its portfolio beyond infectious-disease treatments especially in light of the company's declining hepatitis C drugs sales, The Wall Street Journal observed.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.